The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Cellular therapies for NHL: current challenges and perspectives
Ian Flinn
• 1 Dec 2018
Speaking the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition, held in San Diego, CA, Ian Flinn, MD, PhD, of the Tennessee Oncology, Nashville, TN, discusses his perspective on the promise and challenges of cellular therapy. Dr Flinn highlights the need to continue investigating other immunotherapy and small molecular options, rather than focusing solely on one therapy type.
